Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADH1B | P00325 | 3/20 | 0.67 |
| ▸ | ADH1A | P07327 | 3/20 | 0.67 |
| ▸ | ADH7 | P40394 | 3/20 | 0.67 |
| ▸ | ADH1C | P00326 | 2/20 | 0.67 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.64 |
| ▸ | ADH4 | P08319 | 1/20 | 0.64 |
| ▸ | TSHR | P16473 | 6/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.38 |
| ▸ | RECQL | P46063 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3015888 | 0.96 | ADH1B (0.67) | ADH1BADH1AADH7ADH1CEPHX1 | |
| SCHEMBL8361119 | 0.92 | ADH1B (0.72) | ADH1BADH1AADH7ADH1CEPHX1 | |
| SCHEMBL3135671 | 0.92 | ADH1B (0.72) | ADH1BADH1AADH7ADH1CEPHX1 | |
| SCHEMBL8957786 | 0.92 | ADH1B (0.72) | ADH1BADH1AADH7ADH1CEPHX1 | |
| SCHEMBL7455633 | 0.92 | ADH1B (0.72) | ADH1BADH1AADH7ADH1CEPHX1 | |
| SCHEMBL3027601 | 0.91 | ADH1B (0.60) | ADH1BADH1AADH7ADH1CEPHX1 | |
| SCHEMBL3033436 | 0.89 | ADH1B (0.75) | ADH1BADH1AADH7ADH1CEPHX1 | |
| SCHEMBL9842855 | 0.89 | ADH1B (0.75) | ADH1BADH1AADH7ADH1CEPHX1 | |
| SCHEMBL3032502 | 0.89 | ADH1B (0.75) | ADH1BADH1AADH7ADH1CEPHX1 | |
| SCHEMBL25922474 | 0.89 | ADH1B (0.75) | ADH1BADH1AADH7ADH1CEPHX1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1268444-B1 | 2,4-DI(HETERO-)ARYLAMINO(-OXY)-5-SUBSTITUTED PYRMIDINES AS ANTINEOPLASTIC AGENTS | ASTRAZENECA AB (SE) | 2007-01-17 | — | — | EP | claimed |
| US-6649608-B2 | Cyclin-dependent serine/threonine and focal adhesion kinase inhibitors | ASTRAZENECA AB (SE) | 2003-11-18 | — | — | US | claimed |
| JP-2003525278-A | — | — | 2003-08-26 | — | — | JP | claimed |
| US-20030149266-A1 | 2,4-Di(hetero-)arylamino (oxy)-5-substituted pyrimidines as antineoplastic agents | ASTRAZENECA AB (SE) | 2003-08-07 | — | — | US | claimed |
| EP-1268444-A1 | 2,4-DI(HETERO-)ARYLAMINO(-OXY)-5-SUBSTITUTED PYRMIDINES AS ANTINEOPLASTIC AGENTS | AstraZeneca AB (SE) | 2003-01-02 | — | — | EP | claimed |
| WO-2001064655-A1 | 2, 4-DI(HETERO-)ARYLAMINO (-OXY)-5-SUBSTITUTED PYRIMIDINES AS ANTINEOPLASTIC AGENTS | ASTRAZENECA AB (SE) | 2001-09-07 | — | — | WO | claimed |
| US-4315855-A | Monoazo disperse dyes containing a nitrophenyl group and a homophthalimide group | BASF AKTIENGESELLSCHAFT (DE) | 1982-02-16 | — | — | US | claimed |
| US-20090186871-A1 | Tyrosine kinase inhibitors | MERCK SHARP & DOHME CORP. | 2009-07-23 | — | — | US | disclosed |
| EP-1268444-B1 | 2,4-DI(HETERO-)ARYLAMINO(-OXY)-5-SUBSTITUTED PYRMIDINES AS ANTINEOPLASTIC AGENTS | ASTRAZENECA AB (SE) | 2007-01-17 | — | — | EP | disclosed |
| US-6649608-B2 | Cyclin-dependent serine/threonine and focal adhesion kinase inhibitors | ASTRAZENECA AB (SE) | 2003-11-18 | — | — | US | disclosed |
| US-20030149266-A1 | 2,4-Di(hetero-)arylamino (oxy)-5-substituted pyrimidines as antineoplastic agents | ASTRAZENECA AB (SE) | 2003-08-07 | — | — | US | disclosed |
| EP-0321190-B1 | Silver halide color photographic light-sensitive material | KONISHIROKU PHOTO IND (JP) | 1994-02-09 | — | — | EP | disclosed |
| EP-0318759-B1 | MULTILAYERED ELECTROPHOTOGRAPHICAL RECORDING MATERIAL | BASF Aktiengesellschaft (DE) | 1993-01-27 | — | — | EP | disclosed |
| EP-0320778-A2 | Silver halide photograhic lightsensitive material | KONICA CORPORATION (JP) | 1989-06-21 | — | — | EP | disclosed |
| EP-0318759-A1 | Multilayered electrophotographical recording material | BASF Aktiengesellschaft (DE) | 1989-06-07 | — | — | EP | disclosed |
| EP-0304856-A2 | Silver halide color photograhic light-sensitive material | KONICA CORPORATION (JP) | 1989-03-01 | — | — | EP | disclosed |
| US-4373102-A | Isoindoline dyes, their preparation and use | BASF AKTIENGESELLSCHAFT (DE) | 1983-02-08 | — | — | US | disclosed |
| US-4315855-A | Monoazo disperse dyes containing a nitrophenyl group and a homophthalimide group | BASF AKTIENGESELLSCHAFT (DE) | 1982-02-16 | — | — | US | disclosed |
| EP-0017132-B1 | DYESTUFFS, THEIR PREPARATION AND UTILISATION | BASF Aktiengesellschaft (DE) | 1981-10-14 | — | — | EP | disclosed |
| EP-0017132-A1 | Dyestuffs, their preparation and utilisation | BASF Aktiengesellschaft (DE) | 1980-10-15 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030149266-A1 | 2,4-Di(hetero-)arylamino (oxy)-5-substituted pyrimidines as antineoplastic agents | CDK2, CCNI, CDK1 | ADH1B 4175/4885ADH1A 3713/4885ADH7 4566/4885 |
| US-20090186871-A1 | Tyrosine kinase inhibitors | ABL1, JAK2, ERBB2 | ADH1B 4405/4885ADH1A 4207/4885ADH7 4200/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.